Statement of Changes in Beneficial Ownership (4)
June 10 2020 - 4:05PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Landry Robert E |
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC.
[
REGN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP Finance CFO |
(Last)
(First)
(Middle)
777 OLD SAW MILL RIVER ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/8/2020 |
(Street)
TARRYTOWN, NY 10591
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 6/8/2020 | | M(1) | | 3500 | A | $272.7 | 27873 | D | |
Common Stock | 6/8/2020 | | F(1) | | 2536 | D | $592.43 | 25337 | D | |
Common Stock | 6/8/2020 | | M(1) | | 3500 | A | $272.7 | 28837 | D | |
Common Stock | 6/8/2020 | | F(1) | | 2536 | D | $592.43 | 26301 | D | |
Common Stock | 6/8/2020 | | M(1) | | 2500 | A | $272.7 | 28801 | D | |
Common Stock | 6/8/2020 | | F(1) | | 1811 | D | $592.4 | 26990 | D | |
Common Stock | 6/8/2020 | | M(1) | | 2250 | A | $272.7 | 29240 | D | |
Common Stock | 6/8/2020 | | F(1) | | 1630 | D | $592.43 | 27610 | D | |
Common Stock | 6/8/2020 | | M(1) | | 2250 | A | $272.7 | 29860 | D | |
Common Stock | 6/8/2020 | | F(1) | | 1630 | D | $592.43 | 28230 | D | |
Common Stock | 6/8/2020 | | M(1) | | 1500 | A | $272.7 | 29730 | D | |
Common Stock | 6/8/2020 | | F(1) | | 1086 | D | $592.43 | 28644 | D | |
Common Stock | 6/9/2020 | | S(1) | | 110 | D | $602.38 (2) | 28534 | D | |
Common Stock | 6/9/2020 | | S(1) | | 131 | D | $603.68 (3) | 28403 | D | |
Common Stock | 6/9/2020 | | S(1) | | 50 | D | $604.14 | 28353 | D | |
Common Stock | 6/9/2020 | | S(1) | | 289 | D | $605.14 (4) | 28064 | D | |
Common Stock | 6/9/2020 | | S(1) | | 353 | D | $606.79 (5) | 27711 | D | |
Common Stock | 6/9/2020 | | S(1) | | 619 | D | $607.47 (6) | 27092 | D | |
Common Stock | 6/9/2020 | | S(1) | | 1511 | D | $608.5 (7) | 25581 | D | |
Common Stock | 6/9/2020 | | S(1) | | 681 | D | $609.53 (8) | 24900 | D | |
Common Stock | 6/9/2020 | | S(1) | | 527 | D | $610.25 (9) | 24373 | D | |
Common Stock | | | | | | | | 200 | I | By 401(k) Plan |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Non-Qualified Stock Option (right to buy) | $272.7 | 6/8/2020 | | M (1) | | | 3500 | (10) | 9/9/2023 | Common Stock | 3500 | $0.0 | 15500 | D | |
Non-Qualified Stock Option (right to buy) | $272.7 | 6/8/2020 | | M (1) | | | 3500 | (10) | 9/9/2023 | Common Stock | 3500 | $0.0 | 12000 | D | |
Non-Qualified Stock Option (right to buy) | $272.7 | 6/8/2020 | | M (1) | | | 2500 | (10) | 9/9/2023 | Common Stock | 2500 | $0.0 | 9500 | D | |
Non-Qualified Stock Option (right to buy) | $272.7 | 6/8/2020 | | M (1) | | | 2250 | (10) | 9/9/2023 | Common Stock | 2250 | $0.0 | 7250 | D | |
Non-Qualified Stock Option (right to buy) | $272.7 | 6/8/2020 | | M (1) | | | 2250 | (10) | 9/9/2023 | Common Stock | 2250 | $0.0 | 5000 | D | |
Non-Qualified Stock Option (right to buy) | $272.7 | 6/8/2020 | | M (1) | | | 1500 | (10) | 9/9/2023 | Common Stock | 1500 | $0.0 | 3500 | D | |
Explanation of Responses: |
(1) | Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). |
(2) | Represents volume-weighted average price of sales of 110 shares of Company stock on June 9, 2020 at prices ranging from $602.35 to $602.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. |
(3) | Represents volume-weighted average price of sales of 131 shares of Company stock on June 9, 2020 at prices ranging from $603.33 to $603.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. |
(4) | Represents volume-weighted average price of sales of 289 shares of Company stock on June 9, 2020 at prices ranging from $605.07 to $605.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. |
(5) | Represents volume-weighted average price of sales of 353 shares of Company stock on June 9, 2020 at prices ranging from $606.46 to $606.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. |
(6) | Represents volume-weighted average price of sales of 619 shares of Company stock on June 9, 2020 at prices ranging from $607.00 to $607.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. |
(7) | Represents volume-weighted average price of sales of 1,511 shares of Company stock on June 9, 2020 at prices ranging from $608.14 to $608.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. |
(8) | Represents volume-weighted average price of sales of 681 shares of Company stock on June 9, 2020 at prices ranging from $609.41 to $609.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. |
(9) | Represents volume-weighted average price of sales of 527 shares of Company stock on June 9, 2020 at prices ranging from $610.00 to $610.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. |
(10) | The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Landry Robert E 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 |
|
| EVP Finance CFO |
|
Signatures
|
/s/**Robert E. Landry | | 6/10/2020 |
**Signature of Reporting Person | Date |
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2023 to Sep 2024